JP Morgan Chase
ABVC icon

JP Morgan Chase’s ABVC BioPharma ABVC Stock Holding History

JP Morgan Chase’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2
Closed -$2 – 7482
2023
Q3 		$2 Buy
+2
New +$5 ﹤0.01% 7402

Other funds holding ABVC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase's ABVC Position: Q4 2023 in Review

JP Morgan Chase sold out of ABVC BioPharma (ABVC) in Q4 2023, closing a stake of 2 shares — an estimated $2 sold.

JP Morgan Chase first reported a position in ABVC in Q3 2023 and held it in 1 quarter. The position peaked at $2 in Q3 2023. 8 funds tracked by Wall St. Rank hold ABVC as of Q4 2023.

  • JP Morgan Chase reported no remaining ABVC BioPharma position as of Q4 2023 after selling out during the quarter.
  • JP Morgan Chase sold 2 ABVC BioPharma shares in Q4 2023, an estimated $2.
  • JP Morgan Chase first reported a position in ABVC BioPharma in Q3 2023 and held it in 1 quarter.
  • JP Morgan Chase's ABVC BioPharma position peaked at $2 in Q3 2023.
  • 8 funds tracked by Wall St. Rank held ABVC BioPharma as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.